Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(11):13 Eur Neuropsychopharmacol. 2016 23-Feb;():. 10.1016/j.euroneuro.2016.01.005What this means for my practice?
Busprione reduced the psilocybin-induced VR subscale scores for elementary and complex visual hallucinations. Though at a trend level, buspirone reduced OB subscale scores of derealisation and depersonalisation phenomena, changes in the sense of time, and basic emotions ranging from heightened mood to euphoria and mania-like experiences. These findings suggest that buspirone, through 5-HT1A receptor activation, reduces psilocybin-induced "excitatory" phenomena and visual hallucinations. The absence of effect of ergotamine could have been due to low bioavailability or a lower efficacy in transducing to the 5-HT1A/2A receptor sites. Overall, these findings highlight the important role of 5-HT1A receptors in psilocybin-induced symptoms and provide implications for treating symptoms in schizophrenia and Parkinson's disease using 5-HT1A agonists.
Study Summary
Forty healthy subjects underwent a double-blind, randomized placebo-controlled, within-subject study design to investigate the role of 5-HT1A receptors on the psychological effects of psilocybin. Subjects were placed in two groups where along with placebo and/or psilocybin, they received either buspirone (partial 5-HT1A agonist) or ergotamine (non-hallucinogenic 5-HT2A/1A agonist). Psychological effects were then analyzed using the Altered State of Consciousness rating scale (5D-ASC). Buspirone significantly reduced the 5D-ASC scale score for Visionary Restructuralization which was driven by the subscale scores of elementary and complex visual hallucinations. At a trend level, buspirone reduced the score for Oceanic Boundlessness. Ergotamine did not have any effects on psilocybin-induced 5D-ASC scores.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!
0 of 4 monthly FREE articles unlocked
